Oxford Immunotec Global (OXFD) Receiving Somewhat Favorable Press Coverage, Accern Reports

Headlines about Oxford Immunotec Global (NASDAQ:OXFD) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Oxford Immunotec Global earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.4734884714409 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Oxford Immunotec Global (NASDAQ:OXFD) opened at $12.19 on Monday. Oxford Immunotec Global has a 1-year low of $10.81 and a 1-year high of $19.51. The company has a market cap of $312.73, a PE ratio of -6.03 and a beta of -0.09. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, October 31st. The company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.02. Oxford Immunotec Global had a negative net margin of 45.74% and a negative return on equity of 38.42%. equities research analysts forecast that Oxford Immunotec Global will post -2.17 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on OXFD shares. BidaskClub lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Thursday. Piper Jaffray Companies decreased their target price on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, October 31st. Zacks Investment Research upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. BTIG Research set a $21.00 price objective on Oxford Immunotec Global and gave the stock a “buy” rating in a research note on Monday, December 18th. Finally, ValuEngine lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $19.75.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total value of $40,050.00. Following the completion of the sale, the director now owns 17,778 shares of the company’s stock, valued at $237,336.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 8.11% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Oxford Immunotec Global (OXFD) Receiving Somewhat Favorable Press Coverage, Accern Reports” was originally published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/oxford-immunotec-global-oxfd-receives-daily-coverage-optimism-rating-of-0-12/1813211.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Insider Buying and Selling by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with our FREE daily email newsletter.

 


Latest News

Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Rumor: Braves Show Interest in Reamluto, Yelich
Rumor: Braves Show Interest in Reamluto, Yelich


Leave a Reply

 
© 2006-2018 BBNS.